Melbourne, Australia – 17 October 2025 – CSL has announced that the Science Based Targets initiative (SBTi) has approved CSL’s near-term science-based emissions reduction targets.

These are: 

• CSL commits to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by FY2030 (from a FY2021 base year)*. 

• CSL commits that 73.1% of CSL’s suppliers by emissions – covering Scope 3 categories: purchased goods and services, capital goods, upstream transportation and distribution, business travel, and downstream transportation and distribution – will have science-based targets by FY2030. 

In 2022, CSL announced its initial target to reduce emissions associated with its own operations by 40% by FY2030. This target has since been updated to 42% to align with the SBTi’s reporting period for calendar years. 

Our Scope 3-related target, approved by the SBTi (as outlined above), is part of our broader intention to engage suppliers who account for 67% of all our total Scope 3 emissions. We aim for these suppliers to have Scope 1 and 2 emissions reduction targets aligned** with the SBTi. This broader intention applies to suppliers across all Scope 3 categories. 

“This validation from the SBTi is an important milestone for CSL. We know that responsible management and efficient use of natural resources are key to CSL’s sustainable growth. By embedding shared value into our approach, we aim to deliver meaningful outcomes for patients, the communities we operate in, and the planet”, said Jeffrey Ball, CSL’s Chief Sustainability Officer.

“CSL has been serving patients since 1916, and our commitment to patients and the planet is built for the long term. Many of the people we support live with rare and lifelong conditions, and our medical R&D breakthroughs can take years, even decades, to realise. That’s why our approach to sustainability is enduring, future-focused, and consistent – we’re here for the long term.”

_{*The target boundary includes land-related emissions and removals from bioenergy feedstocks. 
**Either the supplier has SBTi-validated targets, or CSL has conducted due diligence to confirm that the supplier’s targets meet SBTi criteria.} 

About CSL
CSL (ASX: CSL; USOTC: CSLLY) is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 30,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.

Media Contact
Brett Foley
Director of Corporate Communications
Mobile +61 461 464 708
Email: brett.foley@csl.com.au